University Journal of Pre and Paraclinical Sciences
Case report - Blastic Plasmacytoid Dendritic Cell Neoplasm, a rare aggressive haematopoietic tumour with typical presentation
Abstract
Blastic plasmacytoid dendritic cell neoplasm
(BPDCN) is a rare form of haematologic
neoplasm with aggressive clinical
behaviour and is characterized by its typical
immunophenotype and clinical presentation.
There have been many case reports
in the recent past and this entity has
been renamed in the recent WHO classification
of tumours (2008). We report a case
of a 53 yr old male, who presented with
skin lesions since 8 months and misdiagnosed
outside as cutaneous lymphoma
and acute myeloid leukaemia, for which he
underwent chemo-radiotherapy and had
been referred to our institution for further
management. On histopathological evaluation
he was diagnosed to have BPDCN,
this was also confirmed by flow cytometry.
This case is reported for its rarity and potential
for misdiagnosis.
Full Text:
PDFReferences
NL. WHO classification of tumours of
haematopoietic and lymphoid tissues.
France: IARC Press, 2008;
hematopathology- E Jaffe.pdf.
Pagano L, Valentini CG, Pulsoni
A, Fisogni S, Carluccio P, Mannelli F,
et al. Blastic plasmacytoid dendritic
cell neoplasm with leukemic presentation:
an Italian multicenter study.
Haematologica. 2013 Feb 1;98
(2):239–46.
Facchetti F, Ungari M, Marocolo
D, Lonardi S, Vermi W. Blastic plasmacytoid
dendritic cell neoplasm.
Hematology Meeting Reports
(formerly Haematologica Reports)
Niakosari F, Sur M. Agranular
CD4+/CD56+ hematodermic neoplasm:
a distinct entity described in
the recent World Health Organization
-European Organization for Research
and Treatment of Cancer
classification for cutaneous lymphomas.
Arch Pathol Lab Med. 2007;131
(1):149–51.
Eros N, Marschalkó M, Balassa K, Hídvégi
B, Szakonyi J, Ilniczky S, et al. Central
nervous system involvement in
CD4+/CD56+ hematodermic neoplasm: a
report of two cases. J Neurooncol. 2010
Apr;97(2):301–4.
Eros N, Marschalkó M, Balassa K, Hídvégi
B, Szakonyi J, Ilniczky S, et al. Central
nervous system involvement in
CD4+/CD56+ hematodermic neoplasm: a
report of two cases. J Neurooncol. 2010
Apr;97(2):301–4.
Cota C, Vale E, Viana I, Requena L,
Ferrara G, Anemona L, et al. Cutaneous
manifestations of blastic plasmacytoid
dendritic cell neoplasm-morphologic and
phenotypic variability in a series of 33 patients.
Am J Surg Pathol. 2010 Jan;34
(1):75–87.
Jaye DL, Geigerman CM, Herling M,
Eastburn K, Waller EK, Jones D. Expression
of the plasmacytoid dendritic cell
marker BDCA-2 supports a spectrum of
maturation among CD4+ CD56+ hematodermic
neoplasms. Mod Pathol Off J U S
Can Acad Pathol Inc. 2006 Dec;19
(12):1555–62.
Chen J, Zhou J, Qin D, Xu S, Yan X.
Blastic plasmacytoid dendritic cell neoplasm.
J Clin Oncol. 2011;29(2):e27–e29.
Jardin F, Callanan M, Penther D, Ruminy
P, Troussard X, Kerckaert JP, et al.
Recurrent genomic aberrations combined
with deletions of various tumour suppressor
genes may deregulate the G1/S transition
in CD4+ CD56+ haematodermic
neoplasms and contribute to the
aggressiveness of the disease. Leukemia.
;23(4):698–707.
Reimer P, Rüdiger T, Kraemer
D, Kunzmann V, Weissinger F, Zettl
A, et al. What is
CD4+ CD56+ malignancy
and how should it be treated?
Bone Marrow Transplant. 2003;32
(7):637–46.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An Initiative of The Tamil Nadu Dr M.G.R. Medical University